Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer
Head And Neck Cancer
Explore 142 assets in Head And Neck Cancer →Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Compugen Ltd
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04570839CT.gov COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Head And Neck Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer (this asset) | Compugen Ltd | P1/2 | CC · 46 |
| Cis-Diamminedichloroplatinum Ii | ImmunityBio, Inc. | P3 | BB |
| Cetuximab | Pfizer | P3 | BB |
| Cyclophosphamide | Zelluna Immunotherapy AS | P3 | BB |
| Epirubicin | Thomas Jefferson University | P3 | BB |
| Pembrolizumab | Thomas Jefferson University | P3 | BB |
| Carboplatin | Rapa Therapeutics LLC | P3 | BB |
| Nepenthe | Instituto Nacional de Cancer, Brazil | P4 | BB |
| Lidocaine | Instituto Nacional de Cancer, Brazil | P3 | BB |
+41 more in the Head And Neck Cancer cohort
Other indications for Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Cancer | — | P1/2 | CCC · 48 |
| Non-Small Cell Lung Carcinoma | — | P2 | CC · 46 |
| Ovarian Cancer | — | P1/2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [247-Alanine,248-Glutamic Acid,250-Alanine,343-Serine,344-Serine,De-C-Terminal-Lysine], Anti-(Human T Cell Immunoreceptor With Ig And Itim Domains) (Human Monoclonal Bms-986207 ?1-Chain), Disulfide With Human Monoclonal Bms-986207 ?-Chain, Dimer in Head And Neck Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-247-alanine248-glutamic-acid250-alanine343-serine344-serinede-c-terminal-lysine-anti-human-t-cell-immunoreceptor-with-ig-and-itim-domains-human-monoclonal-bms-986207-1-chain-disulfide-with-human-monoclonal-bms-986207-chain-dimer-head-and-neck-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →